Sign In
Buy GCAN
$0.145
-0.0029 (-1.96%)
At Close: Jun 23, 2026
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global dev
GCANRx Announces Relisting To OTCQB Market Tier
07:45am, Wednesday, 03'rd Dec 2025
Baltimore, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTC: GCAN) (“the Company”), a clinical stage biopharmaceutical company focused on the development of new and effect
GCANRx Announces Uplisting to New Market Tier
09:06am, Monday, 30'th Jun 2025
BALTIMORE, June 30, 2025 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannab
GCAN to Explore Strategic Alternatives in Artificial Intelligence and Quantum Computing
08:00am, Thursday, 02'nd Jan 2025
BALTIMORE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next g
Meridian Wealth Management LLC Makes New Investment in InterContinental Hotels Group PLC (NYSE:IHG)
08:00am, Monday, 20'th May 2024
Meridian Wealth Management LLC bought a new position in InterContinental Hotels Group PLC (NYSE:IHG – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing
Dimensional Fund Advisors LP Purchases 140,347 Shares of Tapestry, Inc. (NYSE:TPR)
07:50am, Monday, 20'th May 2024
Dimensional Fund Advisors LP increased its position in shares of Tapestry, Inc. (NYSE:TPR – Free Report) by 4.4% in the fourth quarter, according to the company in its most recent disclosure wit
Koninklijke Philips (NYSE:PHG) Shares Sold by National Bank of Canada FI
05:07am, Monday, 20'th May 2024
National Bank of Canada FI cut its position in Koninklijke Philips (NYSE:PHG – Free Report) by 89.8% during the 4th quarter, according to the company in its most recent filing with the Securitie
GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
07:45am, Tuesday, 27'th Feb 2024
BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation ca
GCANRx Featured in American Journal of Endocannabinoid Medicine
08:29am, Thursday, 21'st Sep 2023
BALTIMORE, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next
GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy
09:45am, Thursday, 19'th Aug 2021
BALTIMORE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTCQB: GCAN) a cannabis innovator specializing in the development of pharmaceutical and
GCANRx Announces Collaboration with Renowned Cannabis Research Lab
09:12am, Tuesday, 16'th Mar 2021
BALTIMORE, March 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company ( OTCQB: GCAN ), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products
